Viral Pneumonia Complications and Management

Immediate Complications and Mortality

• Hospitalized patients with primary viral pneumonia face mortality rates exceeding 40% despite maximal intensive care support, with death typically occurring within 7 days of hospital admission, and rapid progression to respiratory failure is characteristic, with breathlessness developing within 48 hours of fever onset 1, 2
• Secondary bacterial pneumonia is more common than primary viral pneumonia, occurring up to 4 times more frequently, but carries a lower mortality rate of 7-24%, and develops during early convalescence, 4-5 days after initial symptoms, with key bacterial pathogens including S. pneumoniae, S. aureus, and H. influenzae 1, 2
• Mixed viral-bacterial pneumonia carries mortality rates exceeding 40%, similar to primary viral pneumonia, and radiographically shows lobar consolidation superimposed on bilateral diffuse infiltrates 1, 2

Cardiovascular Sequelae

• ECG abnormalities, including ST segment deviation, T wave changes, and rhythm disturbances, occur in up to 81% of hospitalized patients, with most patients lacking cardiac symptoms despite ECG changes, and myocarditis and pericarditis occasionally complicating severe illness 2
• Necrotizing myocarditis has been documented on postmortem examination even without antemortem clinical evidence 2

Management Approach

• The management approach for viral pneumonia includes continuous monitoring of heart rate, pulse oximetry, respiratory rate, and blood pressure, as well as laboratory surveillance of blood counts, CRP, PCT, organ function, coagulation studies, arterial blood gases, and serial chest imaging 3
• Nutritional support stratification is based on nutrition risk score, with a protein-rich diet and early nutritional support with oral supplements or enteral tube feeding for high-risk patients 3
• Respiratory support escalation includes oxygen therapy progression, non-invasive ventilation, and invasive mechanical ventilation, with consideration of ECMO for refractory hypoxemia 3
• Antimicrobial management involves avoiding empiric antibiotics, using amoxicillin, azithromycin, or fluoroquinolones for mild cases with suspected bacterial co-infection, and empirical coverage of all possible pathogens with de-escalation once causative bacteria are identified 3
• Antiviral therapy has limited evidence from randomized controlled trials, but when used, should be initiated as early as possible in the disease course 3
• Corticosteroid use may improve clinical symptoms, reduce disease progression, and accelerate lung lesion absorption in severe cases, but does not shorten hospital stay and carries risk of adverse reactions 3
• Complication prevention includes secretion management with selective M1/M3 receptor anticholinergic drugs, GI prophylaxis with H2 receptor antagonists or proton pump inhibitors, and VTE prophylaxis with low-molecular-weight heparin or heparin in high-risk patients without contraindications 3